Radioembolisation of hepatocellular carcinoma: a primer

Venkatanarasimha, Nanda; Gogna, Apoorva; Tong, Aaron Kian Ti; Damodharan, Karthikeyan; Chow, Pierce K. H.; Lo, Richard Hoau Gong; Chandramohan, Sivanathan

doi:10.1016/j.crad.2017.07.021

Cited by 28 publications

(18 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, individuals who are ineligible for surgery are not the best candidates for percutaneous ablation. If both surgery and RFA are contraindicated, hepatic intra-arterial embolisation with drug-eluting beads might be an option: it has been used in other solid tumours [93] but its efficacy in TC has not been validated. (Figure 4).…”

Section: Management Of Advanced/metastatic Diseasementioning

confidence: 99%

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

et al. 2019

View full text Add to dashboard Cite

Section: Management Of Advanced/metastatic Diseasementioning

confidence: 99%

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

et al. 2019

View full text Add to dashboard Cite

“…Once the microspheres become lodged at the tumor site, localized b-emission radiation treats cancer cells with limited tissue penetrance (range, 2.5-11 mm), sparing liver parenchyma. 19 On the basis of liver explant pathology after radioembolization and subsequent transplantation, 61% of treated lesions (and 89% of lesions <3 cm) exhibited complete pathologic necrosis. 20 In addition to high histopathologic response rates (RR), radioembolization has a reported radiologic RR of 70% for the treatment of HCC, 21 and radiologic RR have been directly correlated with survival.…”

Section: Radioembolizationmentioning

confidence: 99%

The role of external beam radiotherapy in the treatment of hepatocellular cancer

Chino

Stephens

Marin

et al. 2018

Cancer

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is increasing in incidence and mortality. Although the prognosis remains poor, long-term survival has improved from 3% in 1970 to an 18% 5-year survival rate today. This is likely because of the introduction of well tolerated, oral antiviral therapies for hepatitis C. Curative options for patients with HCC are often limited by underlying liver dysfunction/cirrhosis and medical comorbidities. Less than one-third of patients are candidates for surgery, which is the current gold standard for cure. Nonsurgical treatments include embolotherapies, percutaneous ablation, and ablative radiation. Technological advances in radiation delivery in the past several decades now allow for safe and effective ablative doses to the liver. Conformal techniques allow for both dose escalation to target volumes and normal tissue sparing. Multiple retrospective and prospective studies have demonstrated that hypofractionated image-guided radiation therapy, used as monotherapy or in combination with other liver-directed therapies, can provide excellent local control that is cost effective. Therefore, as the HCC treatment paradigm continues to evolve, ablative radiation treatment has moved from a palliative treatment to both a "bridge to transplant" and a definitive treatment.

show abstract

“…In recent years, TARE with yttrium-90 (Y-90) microspheres has become a safe treatment option for unresectable primary and metastatic liver malignancies (6)(7)(8)(9). It may also be preferred as a bridge prior to resection, radiofrequency ablation and liver transplantation (7).…”

Section: Introductionmentioning

confidence: 99%

“…TARE may be helpful in the management of advanced liver malignancies (10)(11)(12)(13). Its palliative role through tumor necrosis and delaying progression has also been shown (6).…”

Section: Introductionmentioning

confidence: 99%

“…TARE is an internal, local, highly selective radiation therapy that has minor embolization effects (14). This treatment modality has less side effects and complications when compared to other local and systemic therapies of liver malignancies with the help of different arterial access to tumor tissue (6,14). In order to decide TARE treatment, complete blood count and biochemical tests including liver and renal function (albumin, total bilirubin, aspartate amino transferase, alanine amino transferase, blood urea nitrogen and creatinine) should be analyzed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Transarterial Y-90 Microsphere Treatment on Biochemical Parameters in Liver Tumors

Yılmaz¹,

Gündoğan²

2019

Istanbul Med J

View full text Add to dashboard Cite

Results: Statistically significant difference was observed only between pre-treatment albumin (albumin 1) and 10 th day albumin (albumin 2), and between pre-treatment albumin (albumin 1) and 3 rd month albumin (albumin 3) levels (p<0.05). There was no statistically significant difference between other biochemical parameters (p>0.05). Conclusion: Albumin value was the most sensitive biochemical parameter in TARE treatment with Y-90 microsphere. It is of great importance that albumin value is frequently followed carefully in these patients.

show abstract

Radioembolisation of hepatocellular carcinoma: a primer

Cited by 28 publications

References 65 publications

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The role of external beam radiotherapy in the treatment of hepatocellular cancer

The Effect of Transarterial Y-90 Microsphere Treatment on Biochemical Parameters in Liver Tumors

Contact Info

Product

Resources

About